In the BioHarmony Drug Report Database

"Preview" Icon

Vedolizumab

Entyvio (vedolizumab) is an antibody pharmaceutical. Vedolizumab was first approved as Entyvio on 2014-05-20. It is used to treat crohn disease, enteritis, and ulcerative colitis in the USA. It has been approved in Europe to treat crohn disease and ulcerative colitis. The pharmaceutical is active against integrin alpha-4 and integrin beta-7.

 

Trade Name

 

Entyvio
 

Common Name

 

vedolizumab
 

ChEMBL ID

 

CHEMBL1743087
 

Indication

 

crohn disease, enteritis, ulcerative colitis
 

Drug Class

 

Monoclonal antibodies: humanized, immunomodulating

Image (chem structure or protein)

Vedolizumab structure rendering